Neurologie

Křídlovická

Study Centre

We have had experience with clinical studies (clinical trials) since 2005. The centre has a doctor’s office, a waiting room and other rooms designed for monitoring, equipment and document archives and records. We have at our disposal a centrifuge, a freezer, a refrigerator, equipment for blood sampling, devices for measuring body functions – ECG, EMG, blood pressure monitor, thermometer, goniometer and others. Medical first aid equipment is a matter of course.

Our permanent medical team includes neurologists and nurses. As part of the studies, we have a designated principal investigator, coordinator and subinvestigators. The team members speak Czech and English. We are able to participate in investigator meetings and other events either in person or online, according to the sponsor’s requirements and according to the agreement with us. We offer speed and flexibility in negotiating contracts and starting the study.

We gained experience with clinical studies both in a university hospital and in a private neurological clinic. The first successfully completed clinical study took place in 2005. So far, we have participated in nearly 20 multicentre international studies, mainly phase III (but also phases II and IV), always with a very high success rate in patient recruitment.

We obtain suitable patients for participation in clinical trials mainly from our own outpatient practice and patient database (over 10 000 patients). Futhermore, for these purposes we are in contact with a number of other doctors, both specialists and general practitioners.

Unlike other providers of studies, we are able to ensure operations even in a serious epidemiological situation, such as the Covid pandemic. Patients are invited to the center individually; in other words,  they do not meet each other.

Please contact our office if you are interested in our services by email. We are looking forward to collaborating with you.

Eduard Minks, MD, PhD

Experience with Pharmacological Multicentre Studies

(sponsor, medicine, phase of study, disease, year)

  • Schwarz Pharma, Rotigotine, phase III, Parkinson disease, 2005-2007
  • Merz, Botulinum toxin A, phase III, Post stroke spasticity, 2006-2007
  • Allergan, Botulinum toxin A, phase III, Cervical dystonia, 2007-2008
  • Novartis, Fingolimod, phase III, Sclerosis multiplex, 2009-2014
  • Merz, Botulinum toxin A, phase III, Post stroke spasticity, 2010-2013
  • Ipsen, Botulinum toxin A, phase III, Cervical dystonia, 2011-2013
  • Allergan, Botulinum toxin A, phase III, Post stroke spasticity, 2012-2015
  • Novartis, Fingolimod, phase III, Sclerosis multiplex, 2014-2015
  • Merz, Botulinum toxin A, phase III, Cerebral palsy, 2014-2017
  • Ipsen, Botulinum toxin A, phase III, Cerebral palsy, 2014-2017
  • Ipsen, Botulinum toxin A, phase III, Post stroke spasticity, 2017-2018
  • Alder, Monoclonal antibody (CGRP), phase III, Chronic mMigraine, 2017-2018
  • Novartis, Angiotensin II type 2 receptor, phase II, Post-herpetic neuralgia, 2018 – 2019
  • Biogen, Inhibitor of voltage-gated sod. ch., phase II, Small fibre neuropathy, 2018 – 2022
  • Merz, Botulinum toxin A, phase III, Spasticity (stroke and brain injury), 2019 – Present
  • Algiax, AP-325 (malononitrilamide), phase II, Peripheral post-surgical neuropathic pain, 2020 – 2024
  • Olainfarm, Neiromidin, phase III, Lumbosacral radiculopathy, 2021 – 2022
  • Janssen Research & Development, Nipocalimab, phase III, Generalized myasthenia
  • Gravis, 2021 – Present 
  • Laboratorios Lesvi, S.L.(Neuraxpharm group), Pregabalin, phase III, Peripheral neuropathic pain, 2022 – 2024